{Economic Information Daily, September 2} CanSino Biologics (06185) (SHA: 688185) announced that its A-shares' closing prices deviated cumulatively by over 30% during three consecutive trading days from September 28 to 30, which constitutes an abnormal stock trading fluctuation. The group stated that there are no material information that should have been disclosed but were not.

   The group noted that it has observed recent market developments regarding mRNA technology, including the release or planned public disclosure of interim clinical data on overseas mRNA cancer vaccines. The group is conducting development of mRNA prophylactic vaccines and therapeutic biologics, as well as related delivery systems. In terms of therapeutic areas, the group is advancing R&D efforts on mRNA vaccines for treating indications such as glioblastoma, rhabdomyosarcoma, and cervical cancer, as well as developing In Vivo CAR-related therapies, all of which are currently in early stages.

   Furthermore, the group confirmed, after verification, that no other major events that might significantly affect the stock price were identified, and that directors, senior management, controlling shareholders and their concert parties did not trade the company's shares during the period of abnormal stock trading fluctuation. (wh)